Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
about
Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populationsClinical pharmacokinetics and pharmacodynamics of linagliptin.Efficacy and safety of linagliptin (tradjenta) in adults with type-2 diabetes mellitus.Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.Pharmacokinetics of linagliptin in subjects with hepatic impairmentPotential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes.Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.Linagliptin: in type 2 diabetes mellitus.Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.Fundamentals of population pharmacokinetic modelling: validation methods.Linagliptin: a review of its use in the management of type 2 diabetes mellitus.Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.Linagliptin: from bench to bedside.Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors.Evaluation of drug efficacy of DPP-4 inhibitors based on theoretical analysis with pharmacokinetics and pharmacodynamics.
P2860
Q26749524-D5EE7CE5-575B-4421-A861-11E8E36C03A4Q34638128-303F28D6-C619-4083-A7EE-0F4EF3E66CE0Q35752928-9523AFE0-657A-4F73-8E6F-AA9B728577BBQ35800419-AB4E9799-6441-4479-90E1-186B194B3203Q36087961-478C26B5-76E3-40C2-86E9-64B4252F4DF9Q36196649-0E3F7C88-965D-408E-9E11-082205742FD2Q37161909-40DD5101-902E-43E7-9434-FED5DE3E26DCQ37858521-95081F7F-C5BC-43F9-AF3D-0FCC402E1CF5Q37878396-D3ED6B7D-7E40-49C1-922A-B89D9266D05FQ37948831-A42970A6-7425-4E40-A911-B2ED39B0C709Q37965613-3C6A3038-D7D5-4EE3-B2B0-EAC4D9FFFF1EQ37982680-87109CF3-D11F-4913-9197-7F879704AC48Q38017726-B6932C73-DDBB-4468-ADD0-78E80216F3A5Q38026590-D368AA68-2060-43C0-A34D-FC3029EF48D8Q38036742-8007056D-7BEB-4BCF-A93B-F37132F537C6Q38078436-8DA02D31-4033-440E-8886-EC218B9CA29EQ38200670-56EE4D7C-A400-4084-82BD-513DD205E313Q38213703-AFE1B7E7-5081-4596-B7D5-8595B53C97F7Q38541323-420BB52E-5A29-43E5-8F73-2CED5547A012Q48152264-955C1963-F7F6-40C8-B818-C98D4F0F4857
P2860
Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Pharmacokinetics and pharmacod ...... 356) in healthy male subjects.
@en
Pharmacokinetics and pharmacodynamics of single rising intravenous doses
@nl
type
label
Pharmacokinetics and pharmacod ...... 356) in healthy male subjects.
@en
Pharmacokinetics and pharmacodynamics of single rising intravenous doses
@nl
prefLabel
Pharmacokinetics and pharmacod ...... 356) in healthy male subjects.
@en
Pharmacokinetics and pharmacodynamics of single rising intravenous doses
@nl
P2093
P1476
Pharmacokinetics and pharmacod ...... 356) in healthy male subjects.
@en
P2093
Alexander Staab
Arvid Jungnik
Klaus A Dugi
Silke Hüttner
Silke Retlich
Ulrich Jaehde
Ulrike Graefe-Mody
Vincent Duval
P304
P356
10.2165/11536620-000000000-00000
P577
2010-12-01T00:00:00Z
P6179
1053060542